Sun Pharma Wins South Africa Nod for Generic Ozempic, Threatening Lilly's Mounjaro
LLY sits 83% above its 52-week low of $623.78 on light trading volume (0.2× avg).
Summary
Sun Pharma secured South African approval to launch a generic semaglutide injection for type 2 diabetes, directly challenging Eli Lilly's Mounjaro in that market. The approval, following India, marks the second market for Sun's generic and comes after Novo Nordisk's semaglutide patent expired in March. Sun plans an imminent launch with 2 mg and 4 mg pre-filled pens. This intensifies competitive pressure on Lilly's obesity and diabetes franchise in South Africa, where compounded versions already erode pricing. The news adds to a string of positive Lilly pipeline updates but introduces a tangible near-term headwind in an emerging market.
At the time of this announcement, LLY was trading at $1,140.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.